Factors influencing the reimbursement decisions of cancer drugs in Spanish National Health System
Pelayo Nieto-Gómez, Celia Castaño-Amores, Antonio José García-Ruiz, Juan Oliva-Moreno · 2026
Read Factors influencing the reimbursement decisions of cancer drugs in Spanish National Health System by Pelayo Nieto-Gómez, Celia Castaño-Amores, Antonio José García-Ruiz, Juan Oliva-Moreno (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13425766.txt.
Description
Pelayo Nieto-Gómez and colleagues study what sways Spain's public choice to pay for cancer drugs for solid tumours between 2010 and 2023. They gathered 220 drug uses approved in that span, scoring added clinical gain with a European oncology scale and value for money from drug prices and quality-adjusted life years.
Other factors weighed were novelty, rival treatments, trial quality, and whether survival and life-quality data were at hand. Health Technology Assessment reports and list prices fed the cost side. Policy readers get a test of which reasons truly move funding, so future cancer funding can be argued on evidence rather than pressure.
Catalog record
| CREATOR | Pelayo Nieto-Gómez, Celia Castaño-Amores, Antonio José García-Ruiz, Juan Oliva-Moreno |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |